AnGes Inc
TSE:4563
Intrinsic Value
AnGes, Inc. engages in the research and development of gene-based medical products. [ Read More ]
The intrinsic value of one AnGes Inc stock under the Base Case scenario is 6.98 JPY. Compared to the current market price of 49 JPY, AnGes Inc is Overvalued by 86%.
Valuation Backtest
AnGes Inc
Run backtest to discover the historical profit from buying and selling AnGes Inc stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
AnGes Inc
Current Assets | 5.9B |
Cash & Short-Term Investments | 4.2B |
Receivables | 26.5m |
Other Current Assets | 1.7B |
Non-Current Assets | 23B |
Long-Term Investments | 355.5m |
PP&E | 423.1m |
Intangibles | 21.7B |
Other Non-Current Assets | 446.5m |
Current Liabilities | 2.5B |
Accounts Payable | 426.4m |
Accrued Liabilities | 130.2m |
Other Current Liabilities | 1.9B |
Non-Current Liabilities | 296.2m |
Long-Term Debt | 214.9m |
Other Non-Current Liabilities | 81.3m |
Earnings Waterfall
AnGes Inc
Revenue
|
153m
JPY
|
Cost of Revenue
|
-133.5m
JPY
|
Gross Profit
|
19.4m
JPY
|
Operating Expenses
|
-12B
JPY
|
Operating Income
|
-12B
JPY
|
Other Expenses
|
4.5B
JPY
|
Net Income
|
-7.4B
JPY
|
Free Cash Flow Analysis
AnGes Inc
Profitability Score
Profitability Due Diligence
AnGes Inc's profitability score is 25/100. The higher the profitability score, the more profitable the company is.
Score
AnGes Inc's profitability score is 25/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
AnGes Inc's solvency score is 67/100. The higher the solvency score, the more solvent the company is.
Score
AnGes Inc's solvency score is 67/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
AnGes Inc
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
AnGes, Inc. engages in the research and development of gene-based medical products. The company is headquartered in Ibaraki-Shi, Osaka-Fu and currently employs 131 full-time employees. The company went IPO on 2002-09-25. The firm is involved in the development of hepatocyte growth factor (HGF) genetic medicines, NF-KB decoy oligo and hemagglutinating virus of Japan envelope (HVJ-E) non-viral vector, among others. As of December 31, 2012, the Company had four consolidated subsidiaries. On January 31, 2013, the Company sold a 95.3% stake of a Osaka-based subsidiary to ISHIHARA SANGYO KAISHA LTD.
Contact
IPO
Employees
Officers
The intrinsic value of one AnGes Inc stock under the Base Case scenario is 6.98 JPY.
Compared to the current market price of 49 JPY, AnGes Inc is Overvalued by 86%.